Posters and Presentations
Peer Review Publications:
Preclinical evaluation of a novel triple-acting PIM/PI3K/mTOR inhibitor, IBL-302, in breast cancer
Sean P. Kennedy, Michael O’Neill, Darren Cunningham, Oncogene(2020), 10 February 2020.
Anti‐tumor effects of PIM/PI3K/mTOR triple kinase inhibitor IBL‐302 in neuroblastoma
Sofie Mohlin, Daniel Bexell, EMBO Molecular Medicine, 16 July 2019.
"Evaluation of dual-acting PIM/PI3K inhibitor IBL-302 in preclinical breast cancer models"
2018 American Association for Cancer Research (AACR) Annual Meeting, April 14-18, 2018 in Chicago.
"Targeting PIM kinase in NSCLC"
International Association of Lung Cancer (IASLC) 16th World Conference on Lung Cancer in Denver, CO September 6-9, 2015.
"Initial Evaluation of Novel Dual PIM/PI3K and Triple PIM/PI3K/MTOR inhibitors in multiple myeloma"
20th Congress of the European Hematology Association (EHA) June 11 – 14, 2015, Vienna.
“Cotargeting of PIM, PI3K and Mtor in Mantle Cell Lymphoma (MCL)”
57th ASH Annual Meeting, Orlando, December 5-8, 2015.
“Combined inhibition of PIM and PI3 kinases shows an enhanced efficacy in a number of solid tumour cell lines”
American Association for Cancer Research (AACR) Annual Meeting 2014, April 5-9, San Diego, California.
“Co-targeting PIM and PI3K/mTOR pathways with a single molecule: Novel orally available combined PIM/PI3K and PIM/PI3K/mTOR kinases inhibitors”
2013 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference, Boston, USA.